Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
Institute for Diagnostic and Interventional Neuroradiology, University Hospital Würzburg, Würzburg, Germany.
J Neurointerv Surg. 2018 Dec;10(12):1192-1196. doi: 10.1136/neurintsurg-2017-013516. Epub 2018 Apr 20.
To assess the clinical safety and efficacy of the Atlas microstent in stent-assisted coil embolization of wide-necked intracranial aneurysms.
Single-center observational study in 36 patients (24 female, 12 male, mean age 56 years) with 37 aneurysms for the endovascular treatment of wide-necked aneurysms. After giving informed consent, patients were included according to the following criteria: aneurysm dome-to-neck ratio <2 or neck diameter >4 mm, and a parent vessel diameter of ≤4.5 mm. Primary endpoint for clinical safety was absence of death, absence of major or minor stroke, and absence of transient ischemic attack. Primary endpoint for treatment efficacy was complete angiographic occlusion according to the Raymond-Roy occlusion classification (RROC) immediately after the procedure.
In 36/37 (97%) cases, the primary endpoint of safety was reached, one patient had a transitory ischemic attack which completely resolved until discharge. In 31/37 (84%) cases, complete occlusion (RROC 1) was reached, and in 6/36 (17%), a residual neck remained (RROC 2). A sequential approach (first stent, then coiling through the same catheter) was used in 21 cases; the other 16 were treated with the jailing technique. Deployment was technically successful in all cases. Follow-up at a median of 6.1 months was available for 29/37 (78%) aneurysms and showed complete occlusion in 27/29 aneurysms (93%) and a neck remnant in 2 cases (7%).
Deployment of the Neuroform Atlas microstent is a safe and effective method for the treatment of intracranial wide-necked aneurysms.
评估 Atlas 微支架在支架辅助弹簧圈栓塞治疗宽颈颅内动脉瘤中的临床安全性和疗效。
对 36 例(24 例女性,12 例男性,平均年龄 56 岁)37 个动脉瘤进行的单中心观察性研究,这些患者均接受了宽颈动脉瘤的血管内治疗。在获得知情同意后,根据以下标准纳入患者:瘤顶颈比<2 或颈直径>4mm,载瘤动脉直径≤4.5mm。临床安全性的主要终点为无死亡、无大或小卒中和无短暂性脑缺血发作。治疗效果的主要终点为即刻根据 Raymond-Roy 闭塞分类(RROC)达到完全血管造影闭塞。
在 37 个病例中的 36 个(97%)达到了安全性的主要终点,1 例患者发生短暂性脑缺血发作,出院时完全缓解。在 37 个病例中的 31 个(84%)达到了完全闭塞(RROC1),6 个(17%)留有残余颈。21 例采用序贯技术(先放置支架,然后通过同一导管进行弹簧圈填塞),其余 16 例采用囚禁技术。所有病例的支架置入均获得技术成功。29 个动脉瘤(78%)获得了中位数为 6.1 个月的随访,27 个动脉瘤(93%)完全闭塞,2 个动脉瘤留有残余颈。
Neuroform Atlas 微支架的置入是治疗颅内宽颈动脉瘤安全有效的方法。